Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G 4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeuti...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2019-11, Vol.37 (32), p.JCO1900210-2999
Hauptverfasser:	Sheng, Xinan, Yan, Xieqiao, Chi, Zhihong, Si, Lu, Cui, Chuanliang, Tang, Bixia, Li, Siming, Mao, Lili, Lian, Bin, Wang, Xuan, Bai, Xue, Zhou, Li, Kong, Yan, Dai, Jie, Wang, Kai, Tang, Xiongwen, Zhou, Huaning, Wu, Hai, Feng, Hui, Yao, Sheng, Flaherty, Keith T, Guo, Jun
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!